person · Reporting owner
LARANJEIRA CHARLES ANTHONY
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Technical Officer | June 14, 2022 | June 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,752 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Exercise / conversion · Acquired 6,000 · Balance 41,752 F1: The option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2028-06-13 | Direct | 9,000 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Exercise / conversion · Disposed 6,000 · Balance 9,000 F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2022 Filed Jun 16, 2022 20:05 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-037399 · doc4.xml · derivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:05 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,000 | $38.35 | $230,100.00 |
DisclosureSEC source: 0001209191-22-037399 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 24,800 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · derivative · entry 7 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2032-06-08 F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 6 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,752 F7 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 267 | $61.98 | $16,548.66 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 5 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,852 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.92 to $62.02, inclusive. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 516 | $60.99 | $31,470.84 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 4 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,119 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.41, inclusive. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,633 | $60.23 | $98,355.59 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 3 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,635 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.80 to $60.76, inclusive. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,521 | $59.08 | $148,940.68 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,268 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.65, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 6. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,813 | $61.37 | $172,645.06 |
DisclosureSEC source: 0001209191-22-035228 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,789 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $44.10 | $0.00 |
DisclosureSEC source: 0001209191-21-066795 · doc4.xml · derivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on May 1, 2018, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,500 | $44.10 | $330,750.00 |
DisclosureSEC source: 0001209191-21-066795 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040086 · doc4.xml · derivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040086 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,681 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:14 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,117 | $61.04 | $129,215.33 |
DisclosureSEC source: 0001209191-21-038881 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,681 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 2 shares of common stock acquired under the issuer's employee stock purchase plan in December 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock · Derivative | 2,500 | $0.00 Strike: $44.10 | $0.00 |
DisclosureSEC source: 0001209191-20-045200 · doc4.xml · derivative · entry 3 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on May 1, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,500 | $52.68 | $131,700.00 |
DisclosureSEC source: 0001209191-20-045200 · doc4.xml · nonDerivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,796 F1 · kind: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 546 shares of common stock acquired under the issuer's employee stock purchase plan in June 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,500 | $44.10 | $110,250.00 |
DisclosureSEC source: 0001209191-20-045200 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $44.10 | $0.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · derivative · entry 11 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on May 1, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · derivative · entry 10 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · derivative · entry 9 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $37.81 | $0.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · derivative · entry 8 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 3,750 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,778 | $52.03 | $92,509.34 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 7 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.10, inclusive. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,859 | $51.77 | $355,090.43 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 6 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,028 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.06 to $51.99, inclusive. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 51,464 | $50.01 | $2,573,714.64 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 5 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,887 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 30,000 | $44.10 | $1,323,000.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 4 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,500 | $43.54 | $326,550.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 3 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 15,000 | $38.35 | $575,250.00 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,750 | $37.81 | $141,787.50 |
DisclosureSEC source: 0001209191-20-039976 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036046 · doc4.xml · derivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036046 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,101 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 01:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 863 | $46.33 | $39,983.65 |
DisclosureSEC source: 0001209191-20-035171 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,101 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes an aggregate of 597 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019 and December 2019. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035098 · doc4.xml · derivative · entry 3 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-05 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035098 · doc4.xml · nonDerivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 430 | $42.91 | $18,451.30 |
DisclosureSEC source: 0001209191-19-035098 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,367 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 559 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038198 · doc4.xml · derivative · entry 2 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038198 · doc4.xml · nonDerivative · entry 1 LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,238 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2019, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.